Executive Office of the President 2012 – Federal Register Recent Federal Regulation Documents
Results 101 - 150 of 298
OMB Sequestration Update Report to the President and Congress for Fiscal Year 2013
Public Law 112-25, the Budget Control Act of 2011 (BCA, ``the Act'') amended the Balanced Budget and Emergency Deficit Control Act of 1985 (BBEDCA) by reinstating the discretionary spending limits that had expired after 2002. Section 254 of the BBEDCA requires the Office of Management and Budget (OMB) to issue a Sequestration Update Report on August 20th of each year on the overall status of discretionary legislation. This report provides OMB's current estimates of the spending limits set in the Act and OMB's scoring of pending appropriations legislation against those limits as of August 2012. As required, these estimates rely on the same economic and technical assumptions used in the President's 2013 Budget, which the Administration transmitted to the Congress on February 13, 2012.
Audits of States, Local Governments, and Non-Profit Organizations; OMB Circular A-133 Compliance Supplement
This notice announces the availability of the 2012 OMB Circular A-133 Compliance Supplement (Supplement). The notice also offers interested parties an opportunity to comment on the 2012 Supplement. The 2012 Supplement adds seven new programs, including four programs added to existing clusters. It deletes eight programs and has also been updated for program changes and technical corrections. The eight deleted programs are:
Revised Meeting Notice: Leadership Meeting on Maternal, Fetal, and Infant Opioid Exposure and Neonatal Abstinence Syndrome
An ONDCP Leadership Meeting on Maternal, Fetal and Infant Opioid Exposure and Neonatal Abstinence Syndrome (NAS) will bring together leaders in the field of policy, opioid exposed infants, pain treatment during pregnancy, and addiction treatment during and after pregnancy. The meeting will be held on Thursday, August 30th 2012 in the Indian Treaty Room, Eisenhower Executive Office Building, 17th Street and Pennsylvania Avenue NW., Washington D.C, 20500 starting at 9:00 a.m. and concluding at 5:30 p.m. The overall objectives of the meeting are to review the state of science and policy and discuss the remaining challenges to the field concerning the upswing in maternal prescription drug abuse and dependence and resulting increases in opioid exposed babies with NAS and possibly other consequences. Misuse and abuse of, and dependence upon, prescription opioid drugs adversely affect the health of millions of Americans and their families. The specific conference objectives are: (1) To share research findings concerning the NAS epidemic and its costs; (2) to begin a national discussion concerning promising and best practices for treating opioid exposed babies; (3) to raise awareness about opioid misuse and dependence during pregnancy and the need for women with drug use disorders to access treatment through family medicine and gynecological practitioners, and specialty treatment providers; (4) to discuss legal and policy issues related to opioid using pregnant women and mothers including barriers to accessing treatment; (5) to promote awareness among regulatory agencies and insurers concerning the risks and benefits of opioids to developing fetuses and the likelihood of neonatal abstinence syndrome resulting from long term opioid use during pregnancy; and (6) to raise awareness about risk prevention opportunities among practitioners and regulators. Members of the public who wish to attend this meeting should telephone ONDCP's Maternal, Fetal, and Infant Opioid Exposure and Neonatal Abstinence Syndrome telephone line at (202) 395-7454 to arrange building access no later than Friday, August 10, 2012. Seating for members of the public is limited and will be assigned on a first come, first served basis. To Attend or For Further Information Contact: Cecelia Spitznas, Ph.D. at (202) 395-7454 or email rsvp@ondcp.eop.gov.
Cost Accounting Standards: Cost Accounting Standards 412 and 413-Cost Accounting Standards Pension Harmonization Rule
The Office of Federal Procurement Policy (OFPP), Cost Accounting Standards Board (Board), is publishing technical corrections to the final rule that revised Cost Accounting Standard (CAS) 412, ``Composition and Measurement of Pension Cost,'' and CAS 413, ``Adjustment and Allocation of Pension Cost'' for the CAS Pension Harmonization Rule, published on December 27, 2011. Some illustrations in that document are not consistent with their corresponding Table or text, or the text used in the two effective date provisions is not consistent with each other in the amendment language. This document corrects the final regulations by revising the applicable sections accordingly.
Request of the U.S. Intellectual Property Enforcement Coordinator for Public Comments: Development of the Joint Strategic Plan on Intellectual Property Enforcement
The Federal Government is starting the process of developing a new Joint Strategic Plan on Intellectual Property Enforcement. By committing to common goals, the U.S. Government will more effectively and efficiently combat intellectual property infringement. In this request for comments, the U.S. Government, through the Office of the U.S. Intellectual Property Enforcement Coordinator (``IPEC''), invites public input and participation in shaping the Administration's intellectual property enforcement strategy. The Office of the U.S. Intellectual Property Enforcement Coordinator was established within the Executive Office of the President pursuant to the Prioritizing Resources and Organization for Intellectual Property Act of 2008, Public Law 110-403 (Oct. 13, 2008) (the ``PRO IP Act''). Pursuant to the PRO IP Act, IPEC is charged with developing the Administration's Joint Strategic Plan on Intellectual Property Enforcement for submission to Congress every three years. In carrying out this mandate, IPEC chairs an interagency intellectual property enforcement advisory committee comprised of Federal departmental and agency heads whose respective departments and agencies are involved in intellectual property enforcement. This request for comments and recommendations as IPEC develops a new enforcement strategy is divided into three parts. In the first section titled ``Strategy Recommendations,'' IPEC requests detailed recommendations from the public regarding specific recommendations for improving the U.S. Government's intellectual property enforcement efforts. In the second section titled ``Threat Assessment,'' IPEC seeks written submissions from the public regarding existing and emerging threats to the protection of intellectual property rights and the identification of threats to public health and safety and the U.S. economy resulting from intellectual property infringement. In the third section titled ``Optional Questions,'' IPEC seeks written submissions from the public to assist IPEC and agencies in the development of specific action items. Responses to this request for comments may be directed to either, or both, of the two sections described above. This request for comments was previously published in the Federal Register on June 26, 2012 (77 FR 38088). This notice extends the period for public comments to August 10, 2012.
Leadership Meeting on Maternal, Fetal, and Infant Opioid Exposure and Neonatal Abstinence Syndrome
An ONDCP Leadership Meeting on Maternal, Fetal and Infant Opioid Exposure and Neonatal Abstinence Syndrome (NAS) will bring together leaders in the field of policy, opioid exposed infants, pain treatment during pregnancy, and addiction treatment during and after pregnancy. The meeting will be held on Thursday, August 30th 2012 at the White House Conference Center at 726 Jackson Place, NW., Washington D.C., starting at 9:00 a.m. and concluding at 5:30 p.m. The overall objectives of the meeting are to review the state of science and policy and discuss the remaining challenges to the field concerning the upswing in maternal prescription drug abuse and dependence and resulting increases in opioid exposed babies with NAS and possibly other consequences. Misuse and abuse of, and dependence upon, prescription opioid drugs adversely affect the health of millions of Americans and their families. The specific conference objectives are: (1) To share research findings concerning the NAS epidemic and its costs; (2) to begin a national discussion concerning promising and best practices for treating opioid exposed babies; (3) to raise awareness about opioid misuse and dependence during pregnancy and the need for women with drug use disorders to access treatment through family medicine and gynecological practitioners, and specialty treatment providers; (4) to discuss legal and policy issues related to opioid using pregnant women and mothers including barriers to accessing treatment; (5) to promote awareness among regulatory agencies and insurers concerning the risks and benefits of opioids to developing fetuses and the likelihood of neonatal abstinence syndrome resulting from long term opioid use during pregnancy; and (6) to raise awareness about risk prevention opportunities among practitioners and regulators. Members of the public who wish to attend the meeting should telephone ONDCP's Maternal, Fetal, and Infant Opioid Exposure and Neonatal Abstinence Syndrome telephone line at (202) 395-7454 to arrange building access. To Attend or For Further Information Contact: Cecelia Spitznas, Ph.D. at (202) 395-7454 or email rsvp@ondcp.eop.gov.
Improving Contracting Officers' Access to Relevant Integrity Information
The Office of Federal Procurement Policy is publishing this notice to advise the public that it has developed a Request for Comment to invite comment from the public on whether changes to current regulations and other guidance might improve contracting officers' access to relevant information about contractor business ethics in the Federal Awardee Performance and Integrity Information System (FAPIIS). FAPIIS is designed to facilitate the Government's ability to evaluate the business ethics of prospective contractors and protect the Government from awarding contracts to contractors that are not responsible sources.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
